Cancer therapies such as chemo and radiotherapy can be extremely aggressive but, for many patients and their clinicians, preserving quality of life is a major factor in choosing their treatment.

Today, there are few in-depth diagnostic methods that can distinguish aggressive tumours - which require intense treatment - from mild tumours.

DoMore Diagnostics is developing technology that analyses tumour tissue to help determine which patients will benefit from additional therapy.

In this episode, we speak to CEO and co-Founder about his journey from consulting firm McKinsey to DoMore Diagnostics.